Brokerages Expect Evoke Pharma Inc (EVOK) to Announce -$0.17 EPS

Wall Street brokerages expect that Evoke Pharma Inc (NASDAQ:EVOK) will report earnings per share of ($0.17) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Evoke Pharma’s earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.19). Evoke Pharma posted earnings per share of ($0.14) in the same quarter last year, which would indicate a negative year-over-year growth rate of 21.4%. The company is scheduled to report its next earnings report on Monday, May 21st.

On average, analysts expect that Evoke Pharma will report full year earnings of $0.11 per share for the current year, with EPS estimates ranging from ($0.42) to $1.16. For the next financial year, analysts anticipate that the business will report earnings of $0.23 per share, with EPS estimates ranging from ($0.83) to $1.85. Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover Evoke Pharma.

How to Become a New Pot Stock Millionaire

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.21.

Several research analysts have recently commented on the company. Zacks Investment Research upgraded Evoke Pharma from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research report on Thursday, March 8th. HC Wainwright set a $9.00 target price on Evoke Pharma and gave the stock a “buy” rating in a research report on Monday. Finally, B. Riley reiterated a “buy” rating and issued a $5.00 target price (down previously from $10.00) on shares of Evoke Pharma in a research report on Thursday, March 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $7.71.

Shares of EVOK traded down $0.08 during mid-day trading on Friday, hitting $2.12. The stock had a trading volume of 12,930 shares, compared to its average volume of 85,932. The firm has a market cap of $34.08, a price-to-earnings ratio of -2.59 and a beta of 1.38. Evoke Pharma has a fifty-two week low of $1.85 and a fifty-two week high of $4.09.

Several hedge funds and other institutional investors have recently made changes to their positions in EVOK. Creative Planning bought a new stake in shares of Evoke Pharma in the 4th quarter worth approximately $226,000. B. Riley Financial Inc. bought a new stake in shares of Evoke Pharma in the 4th quarter worth approximately $249,000. 683 Capital Management LLC bought a new stake in shares of Evoke Pharma in the 4th quarter worth approximately $258,000. Deutsche Bank AG bought a new stake in shares of Evoke Pharma in the 4th quarter worth approximately $452,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Evoke Pharma by 15.1% in the 2nd quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after purchasing an additional 68,544 shares during the last quarter. 18.42% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Brokerages Expect Evoke Pharma Inc (EVOK) to Announce -$0.17 EPS” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3335248/brokerages-expect-evoke-pharma-inc-evok-to-announce-0-17-eps.html.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

onG.social Price Up 25.6% Over Last 7 Days
onG.social Price Up 25.6% Over Last 7 Days
SwftCoin Market Cap Tops $22.12 Million
SwftCoin Market Cap Tops $22.12 Million
Coupecoin   Trading 8.1% Lower  This Week
Coupecoin Trading 8.1% Lower This Week
Zacks: Analysts Anticipate Container Store Group Inc  Will Post Quarterly Sales of $231.21 Million
Zacks: Analysts Anticipate Container Store Group Inc Will Post Quarterly Sales of $231.21 Million
Emphy  Price Reaches $0.15 on Top Exchanges
Emphy Price Reaches $0.15 on Top Exchanges
CanYaCoin Trading 21.5% Higher  This Week
CanYaCoin Trading 21.5% Higher This Week


© 2006-2018 Ticker Report. Google+.